News Ipsen

Equities

IPN

FR0010259150

Real-time Euronext Paris Other stock markets 03:12:20 2024-04-26 am EDT			5-day change	1st Jan Change
112.1 ^EUR	-0.18%		+3.14%	+3.61%

Apr. 24	IPSEN : Better-than-expected Q1; guidance unchanged
Apr. 24	Transcript : Ipsen S.A., Q1 2024 Sales/ Trading Statement Call, Apr 24, 2024

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

IPSEN : Better-than-expected Q1; guidance unchanged	Apr. 24
Ipsen : Q1 2024 – sales presentation (1.17 MB)	Apr. 24	PU
Transcript : Ipsen S.A., Q1 2024 Sales/ Trading Statement Call, Apr 24, 2024	Apr. 24
Ipsen: sales up 11% in Q1	Apr. 24	CF
Ipsen : Q1 2024 – sales announcement (228.28 KB)	Apr. 24	PU
Ipsen : Q1 2024 – highlights (288.70 KB)	Apr. 24	PU
Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance	Apr. 24	GL
Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance	Apr. 24	AQ
Ipsen Teams Up with Skyhawk Therapeutics on Study of RNA Modulator for Rare Neurological Diseases	Apr. 22	MT
Ipsen: collaboration agreement with Skyhawk	Apr. 22	CF
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases	Apr. 22	GL
Ipsen and Skyhawk Therapeutics Announces RNA Targeting Research Collaboration in Rare Neurological Diseases	Apr. 22	CI
Ipsen : 2023 Universal Registration Document	Apr. 18	PU
Ipsen publishes its 2023 Universal Registration Document	Apr. 17	GL
Ipsen publishes its 2023 Universal Registration Document	Apr. 17	AQ
Ipsen: Parvus AM Europe Ltd exceeds 5% of voting rights	Apr. 15	CF
Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen	Apr. 03	AQ
Ipsen: worldwide licensing agreement with Sutro Biopharma	Apr. 02	CF
Ipsen Signs Licensing Deal for Cancer-targeting Antibody Conjugate with Sutro Biopharma	Apr. 02	MT
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors	Apr. 02	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

IPSEN : Better-than-expected Q1; guidance unchanged

April 24, 2024 at 10:50 am EDT